The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

KEYNOTE-204: Pembrolizumab versus brentuximab vedotin R/R classic Hodgkin lymphoma

Jun 1, 2020

During the American Society of Clinical Oncology (ASCO) Annual Meeting, the Lymphoma Hub was pleased to speak to John Kuruvilla, University of Toronto, CA, US. In this video, Dr Kuruvilla discusses the KEYNOTE-204 clinical trial results, investigating the use of pembrolizumab versusbrentuximab vedotin in relapsed/refractory classic Hodgkin lymphoma.

This was a large, randomized phase III study, with progression-free survival as the primary endpoint. Toxicity results were also different among the two treatment groups and pneumonitis results were discussed for pembrolizumab.

KEYNOTE-204: Pembrolizumab versus brentuximab vedotin R/R classic Hodgkin lymphoma